Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series.
Elsevier donates Unified Data Model to The Pistoia Alliance, facilitating data sharing and accelerating research in the life sciences
Elsevier, the information analytics business specializing in science and health, has announced it is donating its Unified Data Model (UDM) to The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D.
Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.
NeuroRx awarded FDA Fast Track Designation for first drug regimen targeting suicide in bipolar depression
NeuroRX , Acute Suicidal Ideation and Behavior (ASIB) , NRX-100 (ketamine HCl) , NRX-100 (ketamine HCl) , NeuroRx, a clinical stage biopharmacompany developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug Administration for its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin enrolling patients in a pivotal trial of this sequential therapy targeting patients who are admitted to Emergency Departments with ASIB in bipolar depression.
Nemera receives Drug Manufacturing Authorization for its Neuenburg plant, in Germany
Nemera received from the German Government Drug Administration (Government Presidium, Tübingen) the Pharmaceutical Drug Manufacturing Authorization according to §13 AMG (German Drug & Medicinal Product Law) at its Neuenburg manufacturing facility in Germany.
VarmX Announces Publication in Nature Communications of Groundbreaking Snake Venom Inspired Approach to Restore Blood Clotting in Patients Using Anticoagulants
VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, announced the publication in Nature Communications of a ground breaking LUMC study(1) on modified human factor X as a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants.
AstraZeneca and Takeda establish collaboration to develop MEDI1341 for Parkinson’s disease
AstraZeneca and Takeda Pharmaceutical Company Limited announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).